Thera-SAbDab

IANALUMAB

>   Structural Summary
TherapeuticIanalumab
TargetTNFRSF13C
Heavy ChainQVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWGWIRQSPGRGLEWLGRIYYRSKWYNSYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARYQWVPKIGVFDSWGQGTLVTVSS
Light ChainDIVLTQSPATLSLSPGERATLSCRASQFILPEYLSWYQQKPGQAPRLLIYGSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQFYSSPLTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II/III
Estimated Status (June '19)Active
Recorded Developmental TechnologyPOTELLIGENT Technology
INN Year Proposed2017
INN Year Recommended2018
Companies InvolvedH. Lee Moffitt Cancer Center and Research Institute, MorphoSys, Novartis
Conditions Approvedna
Conditions ActiveAutoimmune hepatitis, Idiopathic pulmonary fibrosis, Multiple sclerosis, Pemphigus vulgaris, Rheumatoid arthritis, Sjogren's syndrome, Systemic lupus erythematosus, Chronic lymphocytic leukaemia
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]